Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
161 SEK | +23.28% | +22.71% | +7.26% |
Apr. 26 | Nordic Shares Closed Up Friday; Medicover Series B Climbed Highest | DJ |
Apr. 26 | Transcript : Medicover AB, Q1 2024 Earnings Call, Apr 26, 2024 |
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's profit outlook over the next few years is a strong asset.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company does not generate enough profits, which is an alarming weak point.
- The company is in debt and has limited leeway for investment
- With an expected P/E ratio at 947.06 and 447.22 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.26% | 2.2B | B+ | ||
-14.92% | 84.68B | B- | ||
+13.30% | 81.12B | C+ | ||
+10.92% | 29.4B | C+ | ||
-12.71% | 16.73B | B | ||
-3.06% | 16.36B | A- | ||
-2.63% | 14.92B | A- | ||
-31.75% | 11.77B | - | - | |
-1.42% | 11.72B | A- | ||
+27.44% | 11.71B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MCOV B Stock
- Ratings Medicover AB